Head and Neck Cancer :: Erbitux with chemotherapy increases overall survival of head and neck cancer patients
ImClone Systems Incorporated (NASDAQ: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) announced that a first line Phase III study of ERBITUX(R) (Cetuximab) combined with platinum-based chemotherapy met the primary endpoint of increasing overall survival in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).